Studies Recruiting Participants

Acthar for Treatment of Proteinuria

Acthar for Treatment of Proteinuria in Membranous Nephropathy Patients

Contact Kshama Mehta:

650-736-1822
krmehta at stanford.edu

ACTH for treatment of IgA Nephropathy

ACTH for treatment of IgA Nephropathy at High Risk of Progression

Contact Kshama Mehta:

650-736-1822
krmehta at stanford.edu

Study of Losmapimod

Study of Losmapimod to Reduce Proteinuria in Idiopathic Focal Segmental Glomerulosclerosis (FSGS)

Contact Kshama Mehta:

650-736-1822
krmehta at stanford.edu

Nephrotic Syndrome

Nephrotic Syndrome Study Network

Contact Kshama Mehta:

650-736-1822
krmehta at stanford.edu

CureGN

Cure Glomerulonephropathy Network

CureGN is a sample biobanking study that seeks to better understand and define glomerular diseases and their outcomes. It will also work to better understand effective treatments for patients based on disease process. This has the potential to be beneficial to society as a whole by reducing the societal burden of these diseases.

VorapAccess

VorapAccess Research Study

A randomized trial to test the effects of vorapaxar on patients who are going to have a fistula for hemodialysis access.

Type 1 Diabetes

Type 1 diabetes (T1D) adversely affects the skeleton and muscle mass and is associated with increased fracture risk in adults. The incidence of T1D is highest in childhood, a critical window for achievement of peak bone mass; thus, a time for increased vulnerability and possibility for intervention. This  observational study assesses bone health  and leg strength using a variety of tests to identify risk factors for bone and muscle deficits. Results will help to formulate intervention trials to prevent the musculoskeletal complications of T1DM.

Population: Children (ages 10-17 years) with and without type 1 diabetes.

Contact Hilary Seeley:

hseeley@stanford.edu

Cystinosis

Children and adults have multiple risk factors associated with cystinosis, hypothesized to affect bone and muscle in these patients.  This observatinoal study examines the musculoskeletal system using a variety of tests to provide insight into potential mechanisms for abnormal bone development and therapies to improve bone outcomes.  The results will also inform future clinical trials to prevent and treat the musculoskeletal complications of cystinosis.

Population: Children and adults (ages 5-60 years) with and without cystinosis.

Contact Jessica Whalen:

650-683-5287
jwhalen@stanford.edu

Chronic Kidney Disease

Children with chronic kidney disease (CKD) have numerous risk factors for impaired bone acquisition. The effects of this disease on bone mineral density in younger children with advanced CKD are not clear.  This observational study examines the musculoskeletal system in children and young adults groups using the imaging tests, and muscle and strength tests.

Population: Children (ages 5-22 years) with and without CKD.

Contact Candice Sheldon:

candice2@stanford.edu